Hall S M, Gregson N A
Neuropathol Appl Neurobiol. 1978 Mar-Apr;4(2):117-27. doi: 10.1111/j.1365-2990.1978.tb00552.x.
The thymidine analogue, 5-bromodeoxyuridine (BrdU), has been used in an attempt to manipulate experimentally the proliferative response of the Schwann cell population that follows induction of segmental demyelination in the peripheral nervous system. It was found that in the presence of BrdU, a significant number of Schwann cells displayed a susceptibility to the agent, in that they could be 'held' in the pro-myelinated state. It is suggested that there is some regulatory transition requiring the priming of the Schwann cell genome for myelination that occurs before the remyelinating phase of repair can be started, but after the establishment of the Schwann cell/axon relationship.
胸腺嘧啶类似物5-溴脱氧尿苷（BrdU）已被用于尝试通过实验操控外周神经系统节段性脱髓鞘诱导后雪旺细胞群体的增殖反应。研究发现，在BrdU存在的情况下，大量雪旺细胞对该试剂表现出易感性，即它们可被“维持”在髓鞘形成前状态。有人提出，在修复的再髓鞘化阶段开始之前，但在雪旺细胞/轴突关系建立之后，存在某种调节转变，需要启动雪旺细胞基因组以进行髓鞘形成。
